Literature DB >> 23315329

New directions in immunotherapy.

Linda Cox1, Enrico Compalati, Thomas Kundig, Mark Larche.   

Abstract

Allergen immunotherapy (AIT) is effective in reducing the clinical symptoms associated with allergic rhinitis, asthma and venom-induced anaphylaxis. Subcutaneous (SCIT) and sublingual immunotherapy (SLIT) with unmodified allergen extracts are the most widely prescribed AIT regimens. The efficacy of these 2 routes appears comparable, but the safety profile with SLIT is more favorable allowing for home administration and requiring less patient time. However, both require that the treatment is taken regularly over several years, e.g., monthly in a supervised medical setting with SCIT and daily at home with SLIT. Despite the difference in treatment settings, poor adherence has been reported with both routes. Emerging evidence suggests that AIT may be effective in other allergic conditions such as atopic dermatitis, venom sting-induced large local reactions, and food allergy. Research with oral immunotherapy (OIT) for food allergies suggest that many patients can be desensitized during treatment, but questions remain about whether this can produce long term tolerance. Further studies are needed to identify appropriate patients and treatment regimens with these conditions. Efforts to develop safer and more effective AIT for inhalant allergies have led to investigations with modified allergens and alternate routes. Intralymphatic (ILIT) has been shown to produce long-lasting clinical benefits after three injections comparable to a 3-year course of SCIT. Epicutaneous (EPIT) has demonstrated promising results for food and inhalant allergies. Vaccine modifications, such as T cell epitopes or the use of viral-like particles as an adjuvant, have been shown to provide sustained clinical benefits after a relatively short course of treatment compared to the currently available AIT treatments, SLIT and SCIT. These newer approaches may increase the utilization and adherence to AIT because the multi-year treatment requirement of currently available AIT is a likely deterrent for initiating and adhering to treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23315329     DOI: 10.1007/s11882-012-0335-7

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  181 in total

1.  Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1.

Authors:  B M Haselden; E Syrigou; M Jones; D Huston; K Ichikawa; M D Chapman; A B Kay; M Larché
Journal:  J Allergy Clin Immunol       Date:  2001-09       Impact factor: 10.793

2.  Improvement of shrimp allergy after sublingual immunotherapy for house dust mites: a case report.

Authors:  G Cortellini; I Spadolini; A Santucci; V Cova; C Conti; A Corvetta; G Passalacqua
Journal:  Eur Ann Allergy Clin Immunol       Date:  2011-10

3.  Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice.

Authors:  L C Wood; S M Jackson; P M Elias; C Grunfeld; K R Feingold
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity.

Authors:  Alexander C Drew; Nirupama P Eusebius; Linda Kenins; Harini D de Silva; Cenk Suphioglu; Jennifer M Rolland; Robyn E O'hehir
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

5.  Vaccination with genetically engineered allergens prevents progression of allergic disease.

Authors:  V Niederberger; F Horak; S Vrtala; S Spitzauer; M-T Krauth; P Valent; J Reisinger; M Pelzmann; B Hayek; M Kronqvist; G Gafvelin; H Grönlund; A Purohit; R Suck; H Fiebig; O Cromwell; G Pauli; M van Hage-Hamsten; R Valenta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

6.  Oral specific hyposensitization in the management of patients allergic to food.

Authors:  C Patriarca; A Romano; A Venuti; D Schiavino; V Di Rienzo; E Nucera; S Pellegrino
Journal:  Allergol Immunopathol (Madr)       Date:  1984 Jul-Aug       Impact factor: 1.667

7.  Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

Authors:  Deepen Patel; Peter Couroux; Pascal Hickey; Anne Marie Salapatek; Paul Laidler; Mark Larché; Roderick P Hafner
Journal:  J Allergy Clin Immunol       Date:  2012-09-13       Impact factor: 10.793

8.  Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

Authors:  Vassili Soumelis; Pedro A Reche; Holger Kanzler; Wei Yuan; Gina Edward; Bernhart Homey; Michel Gilliet; Steve Ho; Svetlana Antonenko; Annti Lauerma; Kathleen Smith; Daniel Gorman; Sandra Zurawski; Jon Abrams; Satish Menon; Terri McClanahan; Rene de Waal-Malefyt Rd; Fernando Bazan; Robert A Kastelein; Yong-Jun Liu
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

9.  Sublingual desensitization in patients with wasp venom allergy: preliminary results.

Authors:  G Patriarca; E Nucera; C Roncallo; A Aruanno; C Lombardo; M Decinti; L Pascolini; M Milani; A Buonomo; D Schiavino
Journal:  Int J Immunopathol Pharmacol       Date:  2008 Jul-Sep       Impact factor: 3.219

10.  T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity.

Authors:  Adrienne Verhoef; Clare Alexander; A Barry Kay; Mark Larché
Journal:  PLoS Med       Date:  2005-03-29       Impact factor: 11.069

View more
  14 in total

Review 1.  Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.

Authors:  Melina Makatsori; Oliver Pfaar; Ramon Lleonart; Moises A Calderon
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 2.  Venom immunotherapy: an updated review.

Authors:  Darío Antolín-Amérigo; Carmen Moreno Aguilar; Arantza Vega; Melchor Alvarez-Mon
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

Review 3.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

4.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

5.  Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production.

Authors:  Monika Majewska-Szczepanik; Philip W Askenase; Francis M Lobo; Katarzyna Marcińska; Li Wen; Marian Szczepanik
Journal:  J Allergy Clin Immunol       Date:  2016-01-22       Impact factor: 10.793

Review 6.  Food allergy diagnosis and therapy: where are we now?

Authors:  Aleena Syed; Arunima Kohli; Kari C Nadeau
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

Review 7.  Food allergy: immune mechanisms, diagnosis and immunotherapy.

Authors:  Wong Yu; Deborah M Hussey Freeland; Kari C Nadeau
Journal:  Nat Rev Immunol       Date:  2016-10-31       Impact factor: 53.106

Review 8.  Cluster subcutaneous allergen specific immunotherapy for the treatment of allergic rhinitis: a systematic review and meta-analysis.

Authors:  Shaoyan Feng; Ying Xu; Renqiang Ma; Yueqi Sun; Xi Luo; Huabin Li
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

Review 9.  Allergen immunotherapy: routes, safety, efficacy, and mode of action.

Authors:  Jillian Leigh Hochfelder; Punita Ponda
Journal:  Immunotargets Ther       Date:  2013-07-22

Review 10.  Stinging insect allergy: current perspectives on venom immunotherapy.

Authors:  Sian W Ludman; Robert J Boyle
Journal:  J Asthma Allergy       Date:  2015-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.